Schistosomiasis vaccines: A response to a Devils' advocate's view

Parasitology Today

Volumn 16, Issue 8, 2000, Pages 322-323

  Hagan, P ^a   Doenhoff, M J ^b   Wilson, R A ^c   Al Sherbiny, M ^d   Bergquist, R ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF WALES   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Egyptian Reference Diagnostics Centre   (Egypt)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OLTIPRAZ; PRAZIQUANTEL; SCHISTOSOMA VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; SCHISTOSOMIASIS; SHORT SURVEY; VACCINATION;

ANIMALS; ANTIGENS, HELMINTH; CLINICAL TRIALS; HUMANS; SCHISTOSOMA; SCHISTOSOMIASIS; VACCINATION; VACCINES;

SCHISTOSOMA;

EID: 0034255985     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(00)01711-7     Document Type: Note

References (17)

1. B. Gryseels Schistosomiasis vaccines: a Devil’s advocate view Parasitol. Today 16 2000 46 48
2. M. Picquet Efficacy of praziquantel against Schistosoma mansoni in northern Senegal Trans. R. Soc. Trop. Med. Hyg. 92 1998 90 93
3. D. Cioli Chemotherapy of schistosomiasis: an update Parasitol. Today 14 1998 418 422
4. P.G. Fallon Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific Am. J. Trop. Med. Hyg. 51 1994 83 88
5. M. Ismail Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers Am. J. Trop. Med. Hyg. 60 1999 932 935
6. W.D. Smith Prospects for vaccines of helminth parasites of grazing ruminants Int. J. Parasitol. 29 1999 17 24
7. M.W. Lightowlers Eradication of Taenia solium cysticercosis: a role for vaccination of pigs Int. J. Parasitol. 29 1999 811 817
8. A. Muro Fasciola hepatica : vaccination of rabbits with native and recombinant antigens related to fatty acid binding proteins Vet. Parasitol. 69 1997 219 229
9. B. Gryseels Human resistance to schistosome infections: age or experience? Parasitol. Today 10 1994 380 384
10. F.F. Stelman Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal Am. J. Trop. Med. Hyg. 49 1993 701 706
11. J.H. Ouma The development of schistosomiasis mansoni in an immunologically naive immigrant population in Masongaleni, Kenya Parasitology 117 1998 123 132
12. Ribeiro de Jesus, A. et al. Human immune responses to Schistosoma mansoni vaccine candidate ant gen. Infect. Immun . (in press).
13. P. Hagan Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium Nature 349 1991 243 245
14. V. Rodrigues Jr. Genetic control of schistosome infections by the SM1 locus of the 5q31-q33 region is linked to differentiation of type 2 helper T lymphocytes Infect. Immun. 67 1999 4689 4692
15. M.G. Hernandez Paramyosin is a major target of the human IgA response against Schistosoma japonicum Parasite Immunol. 2 1999 641 647
16. F. Mutapi Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection J. Infect. Dis. 178 1998 289 293
17. C.F. Hatz Evolution of Schistosoma haematobium –related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania Am. J. Trop. Med. 59 1998 775 781